
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses On Their Investment In Urogen Pharma Ltd. Of Class Action Lawsuit And Upcoming Deadlines - URGN
The class action concerns whether UroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until July 28, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired UroGen securities during the Class Period. A copy of the Complaint can be obtained at .
[Click here for information about joining the class action]
On May 16, 2025, the U.S. Food and Drug Administration (“FDA”) posted a briefing document for the Oncologic Drugs Advisory Committee meeting, scheduled for May 21, 2025, to discuss the New Drug Application (“NDA”) for UroGen's bladder cancer drug UGN-102 (mitomycin). Among other things, the briefing document said that because the Company's Envision trial lacked a concurrent control arm, the trial's primary endpoints of complete response and duration of response are difficult to interpret. The FDA further stated that it recommended a randomized trial design“several times” to UroGen to assuage these concerns.
On this news, UroGen's stock price fell $2.54 per share, or 25.79%, to close at $7.31 per share on May 16, 2025.
Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the NDA for UGN-102 after finding that the drug's overall benefit-risk profile was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.
On this news, UroGen's stock price fell $3.37 per share, or 44.7%, to close at $4.17 per share on May 21, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Bydfi Joins Seoul Meta Week 2025, Advancing Web3 Vision And South Korea Strategy
- BSGM Engages CXG To Acquire FINRA/SEC-Registered Broker-Dealer To Expand Publicly Traded RWA Tokenization Operations
- NEXBRIDGE And NEXPLACE Raise $8M Series A To Launch Integrated Bitcoin Capital Markets Ecosystem
- New Silver's Income Fund Unveils Monthly Payouts And No Lockup Period
- SAP Fioneer Launches AI Agent To Transform Financial Services Operations
- Galxe Starboard Leads Infofi Boom With 5 Million Engagements
Comments
No comment